Loading...

Buy Full Version
"Influenza Vaccine Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Type (Seasonal and Pandemic), Technology (Egg-based and Cell-based), Age Group (Pediatric and Adult), and Route of Administration (Injection and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2019–2026

A01437
Pages: 226
Oct 2019 | 1638 Views
 
Author(s) : Surabhi Pandey, Snehal Manjrekar , Onkar Sumant
Tables: 145
Charts: 50
 

Influenza Vaccine Market Outlook - 2026

The global influenza vaccine market size was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026.

Influenza is a viral infection of the respiratory system, wherein an infected person suffers from fever, muscle aches, runny nose, cough, congestion, headaches, and fatigue. The four types of influenza viruses include type A, B, C, and D. The type A and B influenza viruses are referred to as human influenza viruses that are majorly responsible for seasonal flu epidemics each year. Type A viruses are further divided into two subtypes and these are named based on differences in two viral surface proteins called hemagglutinin (H) and neuraminidase (N). Influenza type C infections cause a mild respiratory illness and do not cause epidemics, whereas influenza D viruses primarily affect cattle and do not cause illness in people. 

Influenza Vaccine Market

Get more information on this report : Request Sample Pages

Influenza is a rapidly transmissible infection, and is spread through coughs and sneezes of an infected person. According to the Centers for Disease Control and Prevention (CDC), every year in the U.S., on an average 5-20% of the population gets affected from the seasonal influenza virus, and about 36,000 deaths are registered due its complications. Therefore, vaccination serves as ideal method for the prevention of influenza. 

Various licensed seasonal influenza vaccines are available in the market, several of which have been prequalified by the WHO for purchase by the UN agencies. In addition, many vaccines against animal influenza A viruses are under the development phase. According to the Center for Diseases Control and Prevention (CDC), it has been observed that seasonal influenza viruses constantly change, which further leads to modifications in influenza vaccines to combat season-specific viral strains. Therefore, all these factors together are expected to offer remunerative opportunities to the influenza vaccine market players to develop new vaccines every year.

The influenza vaccine market is anticipated to witness significant growth during the forecast period due to increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, funding and investments by companies in R&D activities supplement the growth of the global market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the influenza vaccine market growth. On the contrary, upsurge in routine immunization programs in developed as well as developing countries is projected to provide lucrative opportunities for market expansion.

Vaccine type segment review

Depending on vaccine type, the influenza vaccine market is classified into quadrivalent and trivalent. The quadrivalent segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period, owing to availability of quadrivalent flu vaccines in hospitals due to their cost-effectiveness. In addition, these vaccines are designed to provide enhanced protection against four viral strains, i.e., two strains of influenza A, H1N1 & H3N2; and two strains of influenza B, Victoria & Yamagata. 

Influenza Vaccine Market
By Vaccine Type

Your browser does not support the canvas element.

Quadrivalent holds the dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Technology segment review

On the basis of technology, the market is bifurcated into egg-based and cell-based. The cell-based segment is projected to exhibit the highest growth during the forecast period, due to rise in surgical procedures across the world, owing to the availability of cell banking facilities, which make the process of manufacturing influenza vaccines from the cell-based technique more flexible. In addition, it offers enhanced protection as compared to traditional vaccines. Since the manufacturing is not dependent on egg supply, these vaccines have the potential to improve the effectiveness by eliminating contamination that might occur in egg during the manufacturing vaccines.

Influenza Vaccine Market
By Technology

Your browser does not support the canvas element.

Cell-based segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Region segment review

Region wise, the influenza vaccine market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America garnered the largest market share in 2018, and is expected to retain its dominance throughout the forecast period. This is attributed to increase in prevalence of influenza in the region, increase in government focus on immunization programs, emergence of new vaccines, and advancements in vaccine administration. However, LAMEA is expected to emerge as a lucrative market for influenza vaccines, due to improvement in healthcare facilities, upsurge in disposable income, and rapid economic development.

The report provides a comprehensive market analysis of the key players operating in the global influenza vaccine market, namely, AstraZeneca Plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd, Gamma Vaccines Pty Ltd., GlaxoSmithKline Plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd.

Influenza Vaccine Market
By Region

2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 6.4% during 2019-2026.

Get more information on this report : Request Sample Pages

Key Benefits for Influenza Vaccine Market:

  • This report provides a detailed quantitative analysis of the current influenza vaccine market trends and estimations from 2018 to 2026, which assists to identify the prevailing opportunities. 
  • An in-depth influenza vaccine market analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the influenza vaccine market is provided.
  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current trends and future market potential from 2019 to 2026 in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the global influenza vaccine market.

Influenza Vaccine Market Segments:

By Vaccine type

  • Quadrivalent
  • Trivalent

By Type

  • Seasonal
  • Pandemic

By Technology

  • Egg-based
  • Cell-based

By Age Group

  • Pediatric
  • Adult

By Route of Administration

  • Injection
  • Nasal Spray

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets
3.2.2.    Top winning strategies

3.3.    Porter's five force analysis
3.4.    Market dynamics

3.4.1.    Drivers

3.4.1.1.    High prevalence of influenza
3.4.1.2.    Increase in government focus on immunization programs
3.4.1.3.    Emerging vaccines
3.4.1.4.    Technological progress in vaccine administration

3.4.2.    Restraints

3.4.2.1.    Longer timelines and implementation of stringent regulations
3.4.2.2.    High costs associated with the development of vaccines

3.4.3.    Opportunity

3.4.3.1.    High growth prospects in emerging markets

CHAPTER 4:    INFLUENZA VACCINE MARKET, BY VACCINE TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Quadrivalent

4.2.1.    Key market trends and opportunities
4.2.2.    Market size and forecast
4.2.3.    Market analysis, by country

4.3.    Trivalent

4.3.1.    Key market trends and opportunities
4.3.2.    Market size and forecast
4.3.3.    Market analysis, by country

CHAPTER 5:    INFLUENZA VACCINE MARKET, BY TYPE

5.1.    Overview
5.2.    Seasonal influenza vaccine
5.3.    Pandemic influenza vaccine

CHAPTER 6:    INFLUENZA VACCINE MARKET, BY TECHNOLOGY

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Egg-based

6.2.1.    Market size and forecast
6.2.2.    Market analysis, by country

6.3.    Cell culture

6.3.1.    Market size and forecast, by region
6.3.2.    Market analysis, by country

CHAPTER 7:    INFLUENZA VACCINE MARKET, BY AGE GROUP

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    Pediatric

7.2.1.    Market size and forecast, by region
7.2.2.    Market analysis, by country

7.3.    Adult

7.3.1.    Market size and forecast, by region
7.3.2.    Market analysis, by country

CHAPTER 8:    INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION

8.1.    Overview

8.1.1.    Market size and forecast

8.2.    Injection

8.2.1.    Market size and forecast
8.2.2.    Market analysis, by country

8.3.    Nasal spray

8.3.1.    Market size and forecast
8.3.2.    Market analysis, by country

CHAPTER 9:    GLOBAL INFLUENZA VACCINE MARKET, BY REGION

9.1.    Overview

9.1.1.    Market size and forecast

9.2.    North America

9.2.1.    Key market trends and opportunities
9.2.2.    Market size and forecast, by vaccine type
9.2.3.    Market size and forecast, by technology
9.2.4.    Market size and forecast, by age group
9.2.5.    Market size and forecast, by route of administration
9.2.6.    Market size and forecast, by country

9.2.6.1.    U.S. market size and forecast, by vaccine type
9.2.6.2.    U.S. market size and forecast, by technology
9.2.6.3.    U.S. market size and forecast, by age group
9.2.6.4.    U.S. market size and forecast, by route of administration
9.2.6.5.    Canada market size and forecast, by vaccine type
9.2.6.6.    Canada market size and forecast, by technology
9.2.6.7.    Canada market size and forecast, by age group
9.2.6.8.    Canada market size and forecast, by route of administration
9.2.6.9.    Mexico market size and forecast, by vaccine type
9.2.6.10.    Mexico market size and forecast, by technology
9.2.6.11.    Mexico market size and forecast, by age group
9.2.6.12.    Mexico market size and forecast, by route of administration

9.3.    Europe

9.3.1.    Key market trends and opportunities
9.3.2.    Market size and forecast, by vaccine type
9.3.3.    Market size and forecast, by technology
9.3.4.    Market size and forecast, by age group
9.3.5.    Market size and forecast, by route of administration
9.3.6.    Market size and forecast, by country

9.3.6.1.    Germany market size and forecast, by vaccine type
9.3.6.2.    Germany market size and forecast, by technology
9.3.6.3.    Germany market size and forecast, by age group
9.3.6.4.    Germany market size and forecast, by route of administration
9.3.6.5.    France market size and forecast, by vaccine type
9.3.6.6.    France market size and forecast, by technology
9.3.6.7.    France market size and forecast, by age group
9.3.6.8.    France market size and forecast, by route of administration
9.3.6.9.    UK market size and forecast, by vaccine type
9.3.6.10.    UK market size and forecast, by technology
9.3.6.11.    UK market size and forecast, by age group
9.3.6.12.    UK market size and forecast, by route of administration
9.3.6.13.    Italy market size and forecast, by vaccine type
9.3.6.14.    Italy market size and forecast, by technology
9.3.6.15.    Italy market size and forecast, by age group
9.3.6.16.    Italy market size and forecast, by route of administration
9.3.6.17.    Spain market size and forecast, by vaccine type
9.3.6.18.    Spain market size and forecast, by technology
9.3.6.19.    Spain market size and forecast, by age group
9.3.6.20.    Spain market size and forecast, by route of administration
9.3.6.21.    Rest of Europe market size and forecast, by vaccine type
9.3.6.22.    Rest of Europe market size and forecast, by technology
9.3.6.23.    Rest of Europe market size and forecast, by age group
9.3.6.24.    Rest of Europe market size and forecast, by route of administration

9.4.    Asia-Pacific

9.4.1.    Key market trends and opportunities
9.4.2.    Market size and forecast, by vaccine type
9.4.3.    Market size and forecast, by technology
9.4.4.    Market size and forecast, by age group
9.4.5.    Market size and forecast, by route of administration
9.4.6.    Market size and forecast, by country

9.4.6.1.    Japan market size and forecast, by vaccine type
9.4.6.2.    Japan market size and forecast, by technology
9.4.6.3.    Japan market size and forecast, by age group
9.4.6.4.    Japan market size and forecast, by route of administration
9.4.6.5.    China market size and forecast, by vaccine type
9.4.6.6.    China market size and forecast, by technology
9.4.6.7.    China market size and forecast, by age group
9.4.6.8.    China market size and forecast, by route of administration
9.4.6.9.    India market size and forecast, by vaccine type
9.4.6.10.    India market size and forecast, by technology
9.4.6.11.    India market size and forecast, by age group
9.4.6.12.    India market size and forecast, by route of administration
9.4.6.13.    Australia market size and forecast, by vaccine type
9.4.6.14.    Australia market size and forecast, by technology
9.4.6.15.    Australia market size and forecast, by age group
9.4.6.16.    Australia market size and forecast, by route of administration
9.4.6.17.    South Korea market size and forecast, by vaccine type
9.4.6.18.    South Korea market size and forecast, by technology
9.4.6.19.    South Korea market size and forecast, by age group
9.4.6.20.    South Korea market size and forecast, by route of administration
9.4.6.21.    Rest of Asia-Pacific market size and forecast, by vaccine type
9.4.6.22.    Rest of Asia-Pacific market size and forecast, by technology
9.4.6.23.    Rest of Asia-Pacific market size and forecast, by age group
9.4.6.24.    Rest of Asia-Pacific market size and forecast, by route of administration

9.5.    LAMEA

9.5.1.    Key market trends and opportunities
9.5.2.    Market size and forecast, by vaccine type
9.5.3.    Market size and forecast, by technology
9.5.4.    Market size and forecast, by age group
9.5.5.    Market size and forecast, by route of administration
9.5.6.    Market size and forecast, by country

9.5.6.1.    Brazil market size and forecast, by vaccine type
9.5.6.2.    Brazil market size and forecast, by technology
9.5.6.3.    Brazil market size and forecast, by age group
9.5.6.4.    Brazil market size and forecast, by route of administration
9.5.6.5.    Saudi market size and forecast, by vaccine type
9.5.6.6.    Saudi market size and forecast, by technology
9.5.6.7.    Saudi market size and forecast, by age group
9.5.6.8.    Saudi market size and forecast, by route of administration
9.5.6.9.    South Africa market size and forecast, by vaccine type
9.5.6.10.    South Africa market size and forecast, by technology
9.5.6.11.    South Africa market size and forecast, by age group
9.5.6.12.    South Africa market size and forecast, by route of administration
9.5.6.13.    Rest of LAMEA market size and forecast, by vaccine type
9.5.6.14.    Rest of LAMEA market size and forecast, by technology
9.5.6.15.    Rest of LAMEA market size and forecast, by age group
9.5.6.16.    Rest of LAMEA market size and forecast, by route of administration

CHAPTER 10:    COMPANY PROFILES

10.1.    ASTRAZENECA PLC (ASTRAZENECA)

10.1.1.    Company overview
10.1.2.    Company snapshot
10.1.3.    Operating business segments
10.1.4.    Product portfolio
10.1.5.    Business performance

10.2.    BIODIEM

10.2.1.    Company overview
10.2.2.    Company snapshot
10.2.3.    Operating business segments
10.2.4.    Product portfolio
10.2.5.    Business performance

10.3.    CSL LIMITED (SEQIRUS GMBH)

10.3.1.    Company overview
10.3.2.    Company snapshot
10.3.3.    Operating business segments
10.3.4.    Product portfolio
10.3.5.    Business performance
10.3.6.    Key strategic moves and developments

10.4.    EMERGENT BIOSOLUTIONS

10.4.1.    Company overview
10.4.2.    Company snapshot
10.4.3.    Operating business segments
10.4.4.    Product portfolio
10.4.5.    Business performance

10.5.    F. HOFFMANN-LA ROCHE LTD.

10.5.1.    Company overview
10.5.2.    Company snapshot
10.5.3.    Operating business segments
10.5.4.    Product portfolio
10.5.5.    Business performance

10.6.    GAMMA VACCINES PTY LTD.

10.6.1.    Company overview
10.6.2.    Company snapshot
10.6.3.    Operating business segments
10.6.4.    Product portfolio

10.7.    GLAXOSMITHKLINE PLC

10.7.1.    Company overview
10.7.2.    Company snapshot
10.7.3.    Operating business segments
10.7.4.    Product portfolio
10.7.5.    Business performance
10.7.6.    Key strategic moves and developments

10.8.    MERCK & CO., INC. (MERCK SHARP & DOHME CORP.)

10.8.1.    Company overview
10.8.2.    Company snapshot
10.8.3.    Operating business segments
10.8.4.    Product portfolio
10.8.5.    Business performance

10.9.    NOVARTIS AG

10.9.1.    Company overview
10.9.2.    Company snapshot
10.9.3.    Operating business segments
10.9.4.    Product portfolio
10.9.5.    Business performance

10.10.    PFIZER, INC.

10.10.1.    Company overview
10.10.2.    Company snapshot
10.10.3.    Operating business segments
10.10.4.    Product portfolio
10.10.5.    Business performance
10.10.6.    Key strategic moves and developments

10.11.    SANOFI

10.11.1.    Company overview
10.11.2.    Company snapshot
10.11.3.    Operating business segments
10.11.4.    Product portfolio
10.11.5.    Business performance

10.12.    SINOVAC BIOTECH LTD.

10.12.1.    Company overview
10.12.2.    Company snapshot
10.12.3.    Operating business segments
10.12.4.    Product portfolio
10.12.5.    Business performance

LIST OF TABLES

TABLE 01.    GLOBAL INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2018–2026, ($MILLION)
TABLE 02.    INFLUENZA VACCINE MARKET FOR QUADRIVALENT, BY REGION, 2018–2026, ($MILLION)
TABLE 03.    INFLUENZA VACCINE MARKET FOR TRIVALENT, BY REGION, 2018–2026, ($MILLION)
TABLE 04.    GLOBAL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 05.    EGG-BASED INFLUENZA VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06.    CELL CULTURE INFLUENZA VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07.    GLOBAL INFLUENZA VACCINE MARKET, BY AGE GROUP, 2018–2026, ($MILLION)
TABLE 08.    INFLUENZA VACCINE MARKET FOR PEDIATRIC AGE GROUP, BY REGION, 2018–2026, ($MILLION)
TABLE 09.    INFLUENZA VACCINE MARKET FOR ADULT AGE GROUP, BY REGION, 2018–2026, ($MILLION)
TABLE 10.    GLOBAL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026, ($MILLION)
TABLE 11.    INFLUENZA VACCINE MARKET FOR INJECTION, BY REGION, 2018–2026, ($MILLION)
TABLE 12.    INFLUENZA VACCINE MARKET FOR NASAL SPRAY, BY REGION, 2018–2026, ($MILLION)
TABLE 13.    GLOBAL INFLUENZA VACCINE MARKET BY REGION, 2018-2026, ($MILLION)
TABLE 14.    CANADA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 15.    CANADA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 16.    CANADA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 17.    CANADA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 18.    NORTH AMERICA INFLUENZA VACCINE MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 19.    U.S. INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 20.    U.S. INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 21.    U.S. INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 22.    U.S. INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 23.    CANADA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 24.    CANADA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 25.    CANADA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 26.    CANADA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 27.    MEXICO INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 28.    MEXICO INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 29.    MEXICO INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 30.    MEXICO INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 31.    EUROPE INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 32.    EUROPE INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 33.    EUROPE INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 34.    EUROPE INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 35.    EUROPE INFLUENZA VACCINE MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 36.    GERMANY INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 37.    GERMANY INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 38.    GERMANY INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 39.    GERMANY INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 40.    FRANCE INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 41.    FRANCE INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 42.    FRANCE INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 43.    FRANCE INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 44.    UK INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 45.    UK INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 46.    UK INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 47.    UK INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 48.    ITALY INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 49.    ITALY INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 50.    ITALY INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 51.    ITALY INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 52.    SPAIN INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 53.    SPAIN INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 54.    SPAIN INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 55.    SPAIN INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 56.    REST OF EUROPE INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 57.    REST OF EUROPE INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 58.    REST OF EUROPE INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 59.    REST OF EUROPE INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 60.    ASIA-PACIFIC INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 61.    ASIA-PACIFIC INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 62.    ASIA-PACIFIC INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 63.    ASIA-PACIFIC INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 64.    ASIA-PACIFIC INFLUENZA VACCINE MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 65.    JAPAN INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 66.    JAPAN INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 67.    JAPAN INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 68.    JAPAN INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 69.    CHINA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 70.    CHINA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 71.    CHINA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 72.    CHINA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 73.    INDIA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 74.    INDIA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 75.    INDIA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 76.    INDIA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 77.    AUSTRALIA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 78.    AUSTRALIA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 79.    AUSTRALIA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 80.    AUSTRALIA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 81.    SOUTH KOREA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 82.    SOUTH KOREA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 83.    SOUTH KOREA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 84.    SOUTH KOREA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 85.    REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 86.    REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 87.    REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 88.    REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 89.    LAMEA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 90.    LAMEA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 91.    LAMEA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 92.    LAMEA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 93.    LAMEA INFLUENZA VACCINE MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 94.    BRAZIL INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 95.    BRAZIL INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 96.    BRAZIL INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 97.    BRAZIL INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 98.    SAUDI INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 99.    SAUDI INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 100.    SAUDI INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 101.    SAUDI INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 102.    SOUTH AFRICA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 103.    SOUTH AFRICA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 104.    SOUTH AFRICA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 105.    SOUTH AFRICA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 106.    REST OF LAMEA INFLUENZA VACCINE MARKET BY VACCINE TYPE, 2018-2026, ($MILLION)
TABLE 107.    REST OF LAMEA INFLUENZA VACCINE MARKET BY TECHNOLOGY, 2018-2026, ($MILLION)
TABLE 108.    REST OF LAMEA INFLUENZA VACCINE MARKET BY AGE GROUP, 2018-2026, ($MILLION)
TABLE 109.    REST OF LAMEA INFLUENZA VACCINE MARKET BY ROUTE OF ADMINISTRATION, 2018-2026, ($MILLION)
TABLE 110.    ASTRAZENECA: COMPANY SNAPSHOT
TABLE 111.    ASTRAZENECA: OPERATING SEGMENTS
TABLE 112.    ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 113.    BIODIEM: COMPANY SNAPSHOT
TABLE 114.    BIODIEM: OPERATING SEGMENTS
TABLE 115.    BIODIEM: PRODUCT PORTFOLIO
TABLE 116.    CSL LIMITED: COMPANY SNAPSHOT
TABLE 117.    CSL LIMITED: OPERATING SEGMENTS
TABLE 118.    CSL LIMITED: PRODUCT PORTFOLIO
TABLE 119.    EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 120.    EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 121.    EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO
TABLE 122.    ROCHE: COMPANY SNAPSHOT
TABLE 123.    ROCHE: OPERATING SEGMENTS
TABLE 124.    ROCHE: PRODUCT PORTFOLIO
TABLE 125.    GAMMA VACCINES: COMPANY SNAPSHOT
TABLE 126.    GAMMA VACCINES: OPERATING SEGMENTS
TABLE 127.    GAMMA VACCINES: PRODUCT TYPE PORTFOLIO
TABLE 128.    GSK: COMPANY SNAPSHOT
TABLE 129.    GSK: OPERATING SEGMENTS
TABLE 130.    GSK: PRODUCT PORTFOLIO
TABLE 131.    MERCK.: COMPANY SNAPSHOT
TABLE 132.    MERCK: OPERATING SEGMENTS
TABLE 133.    MERCK: PRODUCT TYPE PORTFOLIO
TABLE 134.    NOVARTIS: COMPANY SNAPSHOT
TABLE 135.    NOVARTIS: OPERATING SEGMENTS
TABLE 136.    NOVARTIS: PRODUCT TYPE PORTFOLIO
TABLE 137.    PFIZER: COMPANY SNAPSHOT
TABLE 138.    PFIZER: OPERATING SEGMENTS
TABLE 139.    PFIZER: PRODUCT TYPE PORTFOLIO
TABLE 140.    SANOFI: COMPANY SNAPSHOT
TABLE 141.    SANOFI: OPERATING SEGMENTS
TABLE 142.    SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 143.    SINOVAC BIOTECH: COMPANY SNAPSHOT
TABLE 144.    SINOVAC BIOTECH: OPERATING SEGMENTS
TABLE 145.    SINOVAC BIOTECH: PRODUCT TYPE PORTFOLIO

LIST OF FIGURES

FIGURE 01.    INFLUENZA VACCINE MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    TOP WINNING STRATEGIES, BY YEAR, 2016–2019*
FIGURE 04.    TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2019* (%)
FIGURE 05.    TOP WINNING STRATEGIES, BY COMPANY, 2016–2019*
FIGURE 06.    LOW-MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.    HIGH BARGAINING POWER OF BUYERS
FIGURE 08.    MODERATE THREAT OF NEW ENTRANTS
FIGURE 09.    MODERATE THREAT OF SUBSTITUTION
FIGURE 10.    HIGH INTENSITY OF COMPETITIVE RIVALRY
FIGURE 11.    TOP IMPACTING FACTORS
FIGURE 12.    COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE FOR QUADRIVALENT, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13.    COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR TRIVALENT, BY COUNTRY,  2018 & 2026 (%)
FIGURE 14.    COMPARATIVE SHARE ANALYSIS OF EGG-BASED INFLUENZA VACCINE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15.    COMPARATIVE SHARE ANALYSIS OF CELL CULTURE INFLUENZA VACCINE MARKET, BY COUNTRY,  2018 & 2026 (%)
FIGURE 16.    COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE FOR PEDIATRIC AGE GROUP, BY COUNTRY,  2018 & 2026 (%)
FIGURE 17.    COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR ADULT AGE GROUP, BY COUNTRY,  2018 & 2026 (%)
FIGURE 18.    COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE FOR INJECTION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19.    COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR NASAL SPRAY, BY COUNTRY,  2018 & 2026 (%)
FIGURE 20.    ASTRAZENECA: REVENUE, 2016–2018 ($MILLION)
FIGURE 21.    ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 22.    ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23.    BIODIEM: REVENUE, 2016–2018 ($MILLION)
FIGURE 24.    CSL LIMITED: REVENUE, 2016–2018 ($MILLION)
FIGURE 25.    CSL LIMITED: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 26.    CSL LIMITED: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 27.    EMERGENT BIOSOLUTIONS: REVENUE, 2016–2018 ($MILLION)
FIGURE 28.    EMERGENT BIOSOLUTIONS: REVENUE SHARE BY PRODUCT, 2018 (%)
FIGURE 29.    EMERGENT BIOSOLUTIONS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 30.    ROCHE: REVENUE, 2016–2018 ($MILLION)
FIGURE 31.    ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 32.    ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 33.    GSK: REVENUE, 2016–2018 ($MILLION)
FIGURE 34.    GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 35.    GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 36.    MERCK: REVENUE, 2016–2018 ($MILLION)
FIGURE 37.    MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38.    MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 39.    NOVARTIS: REVENUE, 2016–2018 ($MILLION)
FIGURE 40.    NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41.    NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42.    PFIZER: REVENUE, 2016–2018 ($MILLION)
FIGURE 43.    PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44.    PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45.    SANOFI: REVENUE, 2016–2018 ($MILLION)
FIGURE 46.    SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47.    SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48.    SINOVAC BIOTECH: REVENUE, 2016–2018 ($MILLION)
FIGURE 49.    SINOVAC BIOTECH: REVENUE SHARE BY PRODUCT, 2018 (%)
FIGURE 50.    SINOVAC BIOTECH: REVENUE SHARE BY REGION, 2018 (%)

 
 

The influenza vaccine industry holds the maximum potential, owing to the increase in R&D activities related to influenza vaccines, growth in immunization programs, and rise in the incidences of influenza globally which, in turn, are responsible to drive the market growth. Furthermore, there have been significant technological advancements in the manufacturing technology of vaccines to improve efficacy and potency of vaccines. High investments by manufacturers to upgrade traditional vaccination production and delivery methods contributes to increased profit margins and achieving operational efficiencies in the production of influenza vaccines, especially in the U.S. However, high cost of vaccines based on recombinant technology and lack of reimbursement in developing countries affects the market growth.

North America accounted for the largest share in 2018 and is anticipated to maintain its lead during the forecast period 2019 to 2026. However, LAMEA exhibits the highest growth rate, as the mean age of the global population is drifting toward older age category and the incidence rate of influenza in patients has drastically increased in the recent years.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Influenza Vaccine Market

  • Online Only
  • $3,456  $3,041
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,379
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370  $4,296
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $4,838
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995  $6,297
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample